Anticancer Drugs Idecabtagene vicleucel Oncology Pharmacology Physiotherapy

Idecabtagene Vicleucel

In this article we will discuss Idecabtagene Vicleucel (Dosage Overview)

In this article, we will discuss Idecabtagene Vicleucel (Dosage Overview). So, let’s get started.


Idecabtagene Vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.


For autologous use only. For intravenous use only.


Idecabtagene Vicleucel is provided as a single dose for infusion containing a suspension of chimeric antigen receptor (CAR)-positive T cells in one or more infusion bags. The recommended dose range is 300 to 460 x 106 CAR-positive T cells.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.